Nocturnal enuresis (Formulary)

Important: Formulation and dosage details

Formulation:

Tablets 200 micrograms

Dosage:

Primary nocturnal enuresis (with normal urine concentrating ability), adult (under 65 years) and child over 5 years.
Tablets: 200 micrograms at bedtime, only increased to 400 micrograms if lower dose ineffective.

Important: Formulation and dosage details

Formulation:

Oral lyophilisates (DesmoMelt^®) 120 micrograms, 240 micrograms

Dosage:

Primary nocturnal enuresis (with normal urine concentrating ability), adult (under 65 years) and child over 5 years.
Oral lyophilisates: sublingually 120 micrograms at bedtime, only increased to 240 micrograms if lower dose ineffective. Withdraw for at least 1 week for reassessment after 3 months.

Important: Formulation and dosage details

Formulation:

Oral lyophilisates (Noqdirna^®) 25 micrograms, 50 micrograms (specialist recommendation)

Dosage:

Noqdirna^® to be initiated only on the recommendation of a urology consultant.  Indicated for patients over 65 years of age with difficult-to-treat nocturnal polyuria who have been referred to urology.

• U+Es for hyponatraemia should be carried out at initiation, 1 week and 1 month
• Follow up every 3 months in primary care
• Include assessment of efficacy; specifically reduced number of nocturnal voids.
• And, if clinically indicated, U+E's to check serum sodium.
• Treatment should be discontinued if there is no reduction in the number of nocturnal voids or where serum sodium falls below 135mmol/L.

As per SMC 1218/17: Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
SMC restriction: For use in patients aged 65 years and over.